Bradley McElroy, MD
Cardiovascular Disease · Paducah, KYNPI 1043248636
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,175 of the $58,184 with a category attached, or 86.2%. Johnson & Johnson accounts for 94.3% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $32,406 and has fallen 100.0% since, to $16 in 2024. Among cardiovascular disease clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $363.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$55K
- Boston Scientific$1K
- Medtronic$337
- Novartis$294
- Amgen$263
- Abiomed$234
- plus $714 from 17 others
What the payments were for
- Consulting fees$3001%
- Speaking & faculty fees$50,17586%
- Travel & lodging$4,6118%
- Food & beverage$3,0465%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 75 | $54,890 |
| Boston Scientific | 5 | $1,452 |
| Medtronic | 3 | $337 |
| Novartis | 15 | $294 |
| Amgen | 14 | $263 |
| Abiomed | 2 | $234 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $110 |
| Abbott | 4 | $101 |
| Sanofi-aventis U.S. LLC | 6 | $88 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Merck | 3 | $46 |
| Boehringer Ingelheim | 3 | $43 |
| Portola Pharmaceuticals, LLC | 2 | $31 |
| AstraZeneca | 2 | $26 |
| Elutia, Inc. | 2 | $25 |
| Pfizer | 2 | $24 |
| Chiesi USA, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Penumbra, Inc. | 1 | $15 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,184 in reported general payments places this provider in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 102 | $93,670 |
| JardianceEmpagliflozin | 77 | $57,017 |
| EntrestoSacubitril/Valsartan | 48 | $53,303 |
| EliquisApixaban | 42 | $32,850 |
| FarxigaDapagliflozin Propanediol | 15 | $21,571 |
| Repatha SureclickEvolocumab | 12 | $7,497 |
| BrilintaTicagrelor | 11 | $6,903 |
| Atorvastatin Calcium | 144 | $1,354 |
| Metoprolol Succinate | 102 | $1,137 |
| ClopidogrelClopidogrel Bisulfate | 96 | $1,119 |
| Carvedilol | 97 | $792 |
| Amlodipine Besylate | 62 | $442 |
| Propafenone Hcl | 11 | $420 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $382 |
| Spironolactone | 33 | $345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $54,890 | $93,670102 claims |
| Boehringer IngelheimJardiance | $43 | $57,01777 claims |
| NovartisEntresto | $294 | $53,30348 claims |
| PfizerEliquis | $24 | $32,85042 claims |
| AstraZenecaFarxiga, Brilinta | $26 | $28,47426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Paducah
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
- Muhammad AkbarBowling Green$84K
- Jeffrey ReichardFlorence$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.